0.91 USD
▼-0.08-7.86%
盘后 0.93 +1.86%
2026-11-19
市值
$560.94M
市盈率
—
EPS
-0.07
股息率
—
52 周区间
0.84 – 2.01
成交量
19.80M
Beta
0.61
目标价
3.50
52W 低 0.8452W 高 2.01
价格走势
公司简介
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clini...
关联新闻
- Geron discontinues late-stage trial of blood cancer drug
Geron said on Wednesday it would discontinue a late-stage trial testing its treatment for patients with a form of rare blood cancer.